South Korea Mucopolysaccharidosis Treatment Market Size, Competitive Landscape, Regional Outlook and Driving Factors Analysis 2028

The South Korea Mucopolysaccharidosis Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global South Korea Mucopolysaccharidosis Treatment market. This report explores all the key factors affecting the growth of the global South Korea Mucopolysaccharidosis Treatment market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141743/

Report Overview

The South Korea Mucopolysaccharidosis treatment market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Mucopolysaccharidoses (MPSs) are a group of inherited metabolic diseases, which are a result of deficiencies in specific lysosomal enzymes that are required for the degradation of glycosaminoglycans (GAGs). It is known that there are eleven genes are causally related to MPS. Deficiency in a specific enzyme results in the accumulation of undegraded GAGs, which causes progressive damage to cells, tissues, and organs. MPS has a broad spectrum of clinical presentations with varied severity and prognosis for different types and individuals. MPS disorders are autosomal recessive, except for MPS II (Hunter syndrome), which has Xlinked inheritance and mainly affects males.

The prevalence of MPS in South Korea population is around 1.35 per 100,000. MPS II is the most prevalent type of MPS (54.6%), followed by MPS III (18.4%), MPS I (15.3%), MPS IV (9.5%), and MPS VI (1.4%).

Market Drivers

The lack of presence of wide range of therapeutics for the patients has led to the domination of enzyme replacement therapy. For instance, Elaprase is the most commonly and widely used drug for mucopolysaccharidosis type II (Hunter Syndrome). Expected launch of cheaper alternatives and advanced therapeutics is likely to drive the growth of South Koreas MPS treatment market. There are a significant number of pipeline candidates for the development of advanced therapeutics for various types of MPS by global players, this will further propel the market drive. High cost of therapeutics along with poor diagnosis rates restrain the market growth.

To Know More About COVID-19 Impact On South Korea Mucopolysaccharidosis Treatment Market @ https://www.prudentmarkets.com/sample-request/141743/

Market Segmentation

By Treatment Type:

Hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are the main treatments for MPS disorders. HSCT is now the only therapy to prevent progressive neurodegenerative disorders in MPS I, II and VII. ERT is currently available for MPS I, II, IVA, VI, and VII, and it has been demonstrated to substantially reduce urinary GAG levels and significantly improve endurance, physiological activities, joint mobility, and quality of life. Additional therapies for MPS disorders are currently in clinical trials, and these include chaperone therapy, substrate reduction therapy, and gene therapy.

By Route of Administration:

According to route of administration market is segmented into intravenous and intracerebroventricular.

Top Players

Some of the key players operating in the MPS treatment market include Takeda Pharmaceutical, BioMarin Pharmaceuticals, Sarepta Therapeutics, GC Pharma, and others. Naglazyme (galsulfase) by BioMarin Pharmaceutical for the treatment of MPS type VI and Elaprase (idursulfase) by Takeda Pharmaceuticals for the treatment of MPS type II hold the monopoly in South Korea market.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141743/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global South Korea Mucopolysaccharidosis Treatment Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global South Korea Mucopolysaccharidosis Treatment Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the South Korea Mucopolysaccharidosis Treatment market
Chapter 2: Exclusive Summary - the basic information of the South Korea Mucopolysaccharidosis Treatment Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the South Korea Mucopolysaccharidosis Treatment
Chapter 4: Presenting the South Korea Mucopolysaccharidosis Treatment Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the South Korea Mucopolysaccharidosis Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141743/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the South Korea Mucopolysaccharidosis Treatment Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.